BICO, the world’s leading bio convergence company, has been granted two patents relating to the regulation and precise control of bioink’s processing temperatures in 3D Bioprinters. The first patent, US 11,046,001, was granted in the United States and relates to temperature regulation of the printbed to enable precise control of the gelation process of bioprinted structures with temperature-sensitive bioinks, such as Collagen and Gelatin. The second patent, SE 543880, was granted in Sweden, and relates to controlling the temperature of the cartridge and dispensing nozzle during 3D bioprinting, leading to increased reproducibility, printing consistency, less downtime due to clogging and less material waste, while achieving a higher cell viability.
“Our mission at BICO is to create the future of medicine and improve health globally through the convergence of key biotechnologies,” says Erik Gatenholm, CEO and co-founder of BICO. “These innovations will help our incredible customers drive advancements across drug discovery, tissue engineering, and disease modeling.”
BICO believes 3D bioprinting will help accelerate drug development and eventually alleviate the strain on organ transplants and this patent is an important milestone in that mission. It is vital during the printing process to maintain a constant printing temperature to keep cells alive. Temperature control is paramount while bioprinting Collagen and Gelatin-based bioinks to avoid clogging the nozzles and have reproducible results. The two patents strengthen the company's protection for intellectual properties and complements a full portfolio of solutions being developed by BICO and its subsidiary CELLINK.
“At BICO we work tirelessly to consistently improve and innovate our bioprinting offerings,” says Dr. Héctor Martínez, co-founder and Chief Technology Officer of BICO. “Our customers around the world are continuously pushing the limits of science using our technology and I’m excited to see how they use these innovations to help make the world a healthier place.”
3D bioprinting is an essential tool for the biofabrication of human tissue models and 3D cell-based assays. As the global 3D bioprinting leader, we have developed breakthrough 3D bioprinting technologies, including extrusion-based bioprinters, light-based bioprinters, tissue-specific bioinks and accessories. The company’s products are in more than 2,000 of the world’s most innovative labs including Stanford, Harvard, Merck, Novartis, AstraZeneca, Johnson & Johnson and others.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
BICO Press office
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601
This information was submitted for publication, through the agency of the contact persons set out above, on October 14, at 15:00 (CEST).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. www.cellink.com